Intraperitoneal therapy of malignant ascites associated with carcinoma of ovary and breast using radioiodinated monoclonal antibody 2G3

This publication has 17 references indexed in Scilit:

• Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites
  European Journal of Cancer and Clinical Oncology, 1991
• Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer.
  Journal of Clinical Oncology, 1990
• Malignant ascites: review of the literature, and an update on monoclonal antibody-targeted therapy
  European Journal of Obstetrics & Gynecology and Reproductive Biology, 1989
• The treatment of intraperitoneal malignant disease with monoclonal antibody guided 131I radiotherapy
  British Journal of Cancer, 1988
• Reactivity of Tumor Cells in Malignant Effusions with a Panel of Monoclonal and Polyclonal Antibodies
  Tumor Biology, 1988
• Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies.
  Journal of Clinical Oncology, 1987
• Characterization of binding of four monoclonal antibodies to the human ovarian adenocarcinoma cell line HEY
  Biochemistry and Cell Biology, 1987
• Determination of the immunoreactive function of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess
  Journal of Immunological Methods, 1984
• Intraperitoneal administration ofcorynebacterium parvum in patients with ascitic ovarian tumors resistant to chemotherapy: Effects on cytotoxicity of tumor-associated macrophages and NK cells
  International Journal of Cancer, 1981
• Intracavitary administration of radioactive isotopes in the control of effusions due to cancer:Results in 267 patients
  Cancer, 1966